Opus Genetics (IRD) Current Assets (2010 - 2026)

Opus Genetics (IRD) has reported Current Assets for 17 consecutive years, with $66.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 38.96% year-over-year to $66.6 million; the TTM figure through Mar 2026 stood at $66.6 million (up 38.96% YoY), while the FY2025 annual figure was $50.0 million, up 36.69% from the prior year.
• Current Assets improved to $66.6 million in Q1 2026 per IRD's latest filing, from $50.0 million in the prior quarter.
• Across five years, Current Assets topped out at $66.6 million in Q1 2026 and bottomed at $14.6 million in Q3 2022.
• Historically, Current Assets has averaged $41.9 million across 5 years, with a median of $44.8 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets slumped 37.22% — and 2023, when it soared 272.14%.
• Opus Genetics' Current Assets stood at $49.0 million in 2022, then advanced by 10.13% to $53.9 million in 2023, then slumped by 32.14% to $36.6 million in 2024, then jumped by 36.69% to $50.0 million in 2025, then jumped by 33.08% to $66.6 million in 2026.
• Business Quant data shows IRD's Current Assets at $66.6 million in Q1 2026, $50.0 million in Q4 2025, and $35.9 million in Q3 2025.